ArticleCancer science2021

Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.

Koji Izutsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.